Ruxolitinib Cream Gets Priority Review for Vitiligo Treatment
The application is supported by data from the phase 3 TRuE-V clinical trial program.
Diagnosis & Disease Information
Opzelura Cream Approved for Nonsegmental Vitiligo
The approval was based on data from two phase 3 studies, which included patients 12 years of age and older with nonsegmental vitiligo who had depigmented areas.
Post-Traumatic Stress in Patients With Vitiligo
The prevalence, severity, and risk factors of post-traumatic stress in patients with vitiligo is assessed.
The Autoimmune Link Between Vitiligo and Celiac Disease
The relationship between vitiligo and celiac disease is reviewed.
FDA Extends Review Period for Ruxolitinib Cream for Vitiligo
The sNDA submission included data from the phase 3 TRuE-V clinical trial program.
Hair Loss in Women is More Than a Cosmetic Concern
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
Repigmentation Observed With Ruxolitinib Cream in Vitiligo Trials
Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.
- Loading...
Loading...
Next post in News
Loading... 
Loading...